Skip to content

Ardelyx ARDX Investment Proceeds

Investment Proceeds at other companies

Mineralys Therapeutics, Inc. logo
Mineralys Therapeutics, Inc.MLYS
$302.5M+764%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$290.26M+0.7%

Other financials

Income statement

See full
Revenue$94.5M+27.5%
Gross profit$89.7M+45.1%
Operating income-$32.8M+9.8%
Net income-$37.6M+8.6%
EPS (diluted)-$0.15+11.8%

Balance sheet

See full
Cash & equivalents$31.2M+1.3%
Total debt$208.3M+34.3%
Total equity$148.6M+2.0%
Total assets$504.5M+23.0%

Cash flow

See full
Operating cash flow-$32.2M+16.2%
CapEx$69.0K-78.8%
Free cash flow-$32.3M+16.7%

Valuation

See full
Market cap$1.53B+25.5%
Enterprise value$1.71B+27.1%
P/S3.6×+0.2×

Profitability

See full
Gross margin92.5%+7.9pp
Operating margin-25.4%
Net margin-13.6%
FCF margin-40.9%

Returns & leverage

See full
Return on equity-39.5%
Debt / equity1.4×+0.3×
Current ratio3.5×-0.6×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.

The official record: Ardelyx’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ardelyx's investment proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ardelyx's investment proceeds?
Ardelyx (ARDX) reported investment proceeds of $37.95M in Q1 2026.
How has Ardelyx's investment proceeds changed year-over-year?
Ardelyx's investment proceeds increased by 9.3% year-over-year, from $34.73M to $37.95M.
What is the long-term trend for Ardelyx's investment proceeds?
Over 4 years (2021 to 2025), Ardelyx's investment proceeds has grown at a 13.9% compound annual growth rate (CAGR), from $125.55M to $211.46M.
What does investment proceeds mean?
Cash received from sales, maturities, and redemptions of investment securities across all categories.